Press release: dupixent approved in the eu as the first-ever targeted therapy for patients with copd

Dupixent approved in the eu as the first-ever targeted therapy for patients with copd first-in-world approval of dupixent for adults with uncontrolled copd with raised blood eosinophils based on two landmark phase 3 studies showing dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life dupixent is the first new treatment approach for copd in more than a decade and a new option for approximately 220,000 adults in the eu approval represents the sixth approved indication for dupixent in the eu and seventh approved indication globally paris and tarrytown, ny, july 3, 2024. the european medicines agency (ema) has approved dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (copd) characterized by raised blood eosinophils.
REGN Ratings Summary
REGN Quant Ranking